嵌合抗原受体
细胞因子释放综合征
医学
肿瘤微环境
癌症研究
免疫学
癌症
免疫系统
癌症免疫疗法
免疫疗法
遗传增强
抗原
细胞疗法
生物
干细胞
内科学
基因
生物化学
遗传学
作者
Elizabeth L. Siegler,Pin Wang
出处
期刊:Human Gene Therapy
[Mary Ann Liebert]
日期:2018-05-01
卷期号:29 (5): 534-546
被引量:59
摘要
Cancer immunotherapy has enormous potential in inducing long-term remission in cancer patients, and chimeric antigen receptor (CAR)-engineered T cells have been largely successful in treating hematological malignancies in the clinic. CAR-T therapy has not been as effective in treating solid tumors, in part due to the immunosuppressive tumor microenvironment. Additionally, CAR-T therapy can cause dangerous side effects, including off-tumor toxicity, cytokine release syndrome, and neurotoxicity. Animal models of CAR-T therapy often fail to predict such adverse events and frequently overestimate the efficacy of the treatment. Nearly all preclinical CAR-T studies have been performed in mice, including syngeneic, xenograft, transgenic, and humanized mouse models. Recently, a few studies have used primate models to mimic clinical side effects better. To date, no single model perfectly recapitulates the human immune system and tumor microenvironment, and some models have revealed CAR-T limitations that were contradicted or missed entirely in other models. Careful model selection based on the primary goals of the study is a crucial step in evaluating CAR-T treatment. Advancements are being made in preclinical models, with the ultimate objective of providing safer, more effective CAR-T therapy to patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI